(no title)
daemonk | 1 year ago
Illumina machines are cost efficient in terms of cost per basepair, but only at large batches. They are trying to rectify this after seeing other benchtop sequencing machines (Element Biosci) moving into the mid-throughout niche and doing well. Their solution is the miseq i100 that they just announced.
But at the end of the day, these are all still constrained by having to think in terms of multiplexed batches which has a lot of operational complexity involved (equi-molar pooling, barcoding, etc).
Ultimately, for commercial sequencing labs, one of the more difficult problem to solve is the operational complexity of how to optimally load the sequencer for lowest cost while balancing failure rates/low coverage rates rather than the technicalities of dna prep/lib prep. Given unlimited and consistent intake samples, the problem gets easier. But most labs have some kind of seasonality or project cycle built in which means it’s not about maximizing a yearly capacity, it’s more about how many samples max you can pump through within a few days.
No comments yet.